William P. Sheridan - Mar 10, 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Chief Medical Officer
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Mar 10, 2022
Transactions value $
-$2,241,960
Form type
4
Date filed
3/14/2022, 04:21 PM
Previous filing
Dec 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $478K +148K +291.98% $3.22 199K Mar 10, 2022 Direct
transaction BCRX Common Stock Sale -$2.69M -160K -80.23% $16.87 39.4K Mar 10, 2022 Direct F1
transaction BCRX Common Stock Sale -$24.7K -1.4K -3.56% $17.64 38K Mar 10, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -148K -100% $0.00* 0 Mar 10, 2022 Common Stock 148K $3.22 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.53 to $17.52. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F2 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.53 to $17.79. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.